Further evidence for effectiveness of nevirapine in reducing mother-to-child HIV-1 tr...( A follow-up study among mothers with HI...),Health

A follow-up study among mothers with HIV-1 and their infants in this week's issue of THE LANCET provides further evidence for the sustained efficacy of nevirapine as a low-cost option to help prevent vertical HIV-1 transmission from mothers to newborn children in less-developed countries.

The provision of antiretroviral therapy to women at the onset of labour and for a short period postnatally to the infant is thought to be sufficient to decrease vertical transmission around the time of childbirth and the start of breastfeeding. This might offer a more affordable approach for HIV-1 infected pregnant women in less-developed countries. The HIVNET 012 study team reported in 1999 that a single-dose intrapartum and neonatal nevirapine regimen significantly decreased the risk of transmission of HIV-1 from mother to child by 47% compared with a short intrapartum/neonatal zidovudine regimen when 87% of babies in the trial had reached age 14-16 weeks. The same investigators led by Brookes Jackson from Makerere University-Johns Hopkins University Research Collaboration (part of the NIH funded HIV Prevention Trials Network) report the safety and efficacy of the nevirapine regimen in all study mothers up to six weeks after delivery and for all babies up to 18 months of age.

From late 1997 to early 1999, HIV-1 infected pregnant women in Kampala, Uganda, were randomly assigned nevirapine (200 mg at labour onset and 2 mg/kg for babies within three days of birth) or zidovudine (600 mg orally at labour onset and 300 mg every 3 hours until delivery, and 4 mg/kg orally twice daily for babies for 7 days). Infant HIV-1 testing was done at birth, age 6-8 and 14-16 weeks, and age 12 months.

645 mothers were enrolled in the study, half received nevirapine, the other half received zidovudine. 99% of babies were breastfed for an average of nine months. Infants were around 40% less likely to have had maternal HIV-1 infection up to 18 months of age if mothers and infan
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
11-Sep-2003

Page: 1 2
Related medicine news :

1. Further evidence reveals the association between periodontal disease and coronary artery disease
2. Further evidence showing treatment benefits of beta interferon for MS
3. Further studies comparing rehydration therapies would waste resources, say researchers
4. Further evidence that HRT does not protect against cardiovascular disease
5. Further evidence linking suicide risk to family history (p 1126)
6. Further evidence of increase in allergic disease in western countries
7. Further Evidence On The Effect Of The UK Cervical Screening Programme
8. Holding Policy Is Cost-Effective Way To Further Protect Blood Plasma Supply From HIV And Other Infections
9. Jefferson Physician Warns Further Study Of DHEAs Safety Needed
10. More evidence of cannabis-induced psychosis
11. Not enough evidence that multivitamins prevent infections in the elderly